Aplidin reduces growth of anaplastic thyroid cancer xenografts and the expression of several angiogenic genes

Angiogenesis in cancer and other diseases

2000 • 8,734 citations

The transcription factor Snail controls epithelial–mesenchymal transitions by repressing E-cadherin expression

2000 • 3,504 citations

Vascular Endothelial Growth Factor Regulates Endothelial Cell Survival through the Phosphatidylinositol 3′-Kinase/Akt Signal Transduction Pathway

1998 • 1,963 citations

Cancer Incidence and Survival among Children and Adolescents: United States SEER Program 1975-1995

1999 • 1,895 citations

Vascular Permeability Factor/Vascular Endothelial Growth Factor and the Significance of Microvascular Hyperpermeability in Angiogenesis

1999 • 752 citations

Antitumor compounds from tunicates

2000 • 324 citations

Treatment of Anaplastic Thyroid Carcinoma with Paclitaxel: Phase 2 Trial Using Ninety-Six-hour Infusion

2000 • 298 citations

Anaplastic carcinoma of the thyroid

1999 • 212 citations

The vasoinhibitory activity of bovine chromogranin A fragment (vasostatin) and its independence of extracellular calcium in isolated segments of human blood vessels

1992 • 187 citations

Antibacterial and Antifungal Activities of Vasostatin-1, the N-terminal Fragment of Chromogranin A

2000 • 166 citations

Combined doxorubicin, hyperfractionated radiotherapy, and surgery in anaplastic thyroid carcinoma. Report on two protocols

1994 • 158 citations

Intensity of vascular endothelial growth factor expression is associated with increased risk of recurrence and decreased disease-free survival in papillary thyroid cancer

2001 • 151 citations

Antiproliferative effect of dehydrodidemnin B (DDB), a depsipeptide isolated from Mediterranean tunicates

1996 • 141 citations

Aplidine, a new anticancer agent of marine origin, inhibits vascular endothelial growth factor (VEGF) secretion and blocks VEGF-VEGFR-1 (flt-1) autocrine loop in human leukemia cells MOLT-4

2003 • 141 citations

GTP-dependent binding of the antiproliferative agent didemnin to elongation factor 1 alpha.

1994 • 136 citations

Vascular endothelial growth factor

1998 • 134 citations

Production and Activation of Matrix Metalloproteinase-2 in Proliferative Diabetic Retinopathy

2003 • 121 citations

Structure and Characterization of the Human Tissue Inhibitor of Metalloproteinases-2 Gene

1996 • 119 citations

The Expression of Vascular Endothelial Growth Factor and the Type 1 Vascular Endothelial Growth Factor Receptor Correlate with the Size of Papillary Thyroid Carcinoma in Children and Young Adults

2000 • 111 citations

Beyond Radioiodine: A Review of Potential New Therapeutic Approaches for Thyroid Cancer

2003 • 97 citations

Practical Management of Pediatric Ocular Disorders and Strabismus

2016 • 92 citations

Progress in the clinical development of new marine-derived anticancer compounds

2004 • 89 citations

Serum Vascular Endothelial Growth Factor Levels Are Elevated in Metastatic Differentiated Thyroid Cancer but Not Increased by Short-Term TSH Stimulation

2002 • 86 citations

Antineoplastic activity of taxol against human anaplastic thyroid carcinoma cell lines in vitro and in vivo.

1996 • 85 citations

Antiangiogenic activity of aplidine, a new agent of marine origin

2004 • 85 citations

In vitro activity of aplidine, a new marine-derived anti-cancer compound, on freshly explanted clonogenic human tumour cells and haematopoietic precursor cells

1998 • 84 citations

Chromogranin A Fragments Modulate Cell Adhesion

1997 • 77 citations

Biochemical and cellular effects of didemnins A and B.

1984 • 74 citations

Combretastatin A4 Phosphate Has Primary Antineoplastic Activity Against Human Anaplastic Thyroid Carcinoma Cell Lines and Xenograft Tumors

2002 • 74 citations

Vascular Endothelial Growth Factor Monoclonal Antibody Inhibits Growth of Anaplastic Thyroid Cancer Xenografts in Nude Mice

2002 • 70 citations

Cytotoxicity and neurocytotoxicity of new marine anticancer agents evaluated using in vitro assays

1999 • 69 citations

Cell cycle phase perturbations and apoptosis in tumour cells induced by aplidine

2002 • 57 citations

Clinical Relevance of Vascular Endothelial Growth Factor for Thyroid Neoplasms

2001 • 44 citations

Systemic administration of vascular endothelial growth factor monoclonal antibody reduces the growth of papillary thyroid carcinoma in a nude mouse model.

2003 • 40 citations

In vitro cytotoxicity of aplidin and crossresistance with other cytotoxic drugs in childhood leukemic and normal bone marrow and blood samples: a rational basis for clinical development

2003 • 29 citations

Pharmaceutical development of a parenteral lyophilized formulation of the novel antitumor agent aplidine.

2000 • 28 citations

Therapeutic efficacy of the angiogenesis inhibitor O- (Chloroacetyl- carbamoyl) fumagillol (TNP-470; AGM-1470) for human anaplastic thyroid carcinoma in nude mice

1997 • 28 citations

Bioanalysis of aplidine, a new marine antitumoral depsipeptide, in plasma by high-performance liquid chromatography after derivatization with trans-4′-hydrazino-2-stilbazole

1999 • 19 citations

Transforming Growth Factor‐β Type II Receptors and Smad Proteins in Follicular Thyroid Tumors

2000 • 19 citations

Analysis of aplidine (dehydrodidemnin B), a new marine-derived depsipeptide, in rat biological fluids by liquid chromatography–tandem mass spectrometry

1999 • 19 citations

Conformational Analysis of Dehydrodidemnin B (Aplidine) by NMR Spectroscopy and Molecular Mechanics/Dynamics Calculations

2001 • 19 citations

Compatibility and stability of aplidine, a novel marine-derived depsipeptide antitumor agent, in infusion devices, and its hemolytic and precipitation potential upon i.v. administration

1999 • 18 citations

Cell cycle arrest and clonogenic tumor cell kill by divergent chemotherapeutic drugs.

2000 • 18 citations

Tumor angiogenesis factors produced by cancer cells.

1999 • 13 citations

Analysis of TGF-β and TGF-β-RII in thyroid neoplasms from the United States, Japan, and China

1998 • 9 citations

Changes in gene expression profile induced by the anticancer agent Aplidine in Molt-4 leukemic cell lines.

2002 • 8 citations

Chemotherapy of Anaplastic Thyroid Cancer

2000 • 5 citations